Last reviewed 2026-05-14 · How we verify
Home › Drugs › Multiple Myeloma Research Consortium › Erdafitinib, dexamethasone, ixazomib, pomalidomide Erdafitinib, dexamethasone, ixazomib, pomalidomide
At a glance
Generic name Erdafitinib, dexamethasone, ixazomib, pomalidomide Also known as erdafitinib: G-024, JNJ-42756493, JNJ-493, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst Sponsor Multiple Myeloma Research Consortium Modality Small molecule Phase Phase 1
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
Drug Landscape https://druglandscape.com/drug/erdafitinib-dexamethasone-ixazomib-pomalidomide · Machine-readable: markdown · JSON · Editorial policy: /editorial-policy
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.